Floxuridine

Floxuridine (5-Fluorouracil 2'-deoxyriboside) is a?pyrimidine?analog?and known as an?oncology antimetabolite. Floxuridine inhibits Poly(ADP-Ribose) polymerase and induces DNA damage by activating the ATM and ATR checkpoint signaling pathways in vitro. Floxuridine is a extreamly potent inhibitor for S. aureus infection and induces cell apoptosis^[1][2]. Floxuridine has antiviral effects against HSV and CMV^[3]. IC50 & Target:IC50: Poly(ADP-Ribose) polymerase; bacterial; apoptosis^[1][2] In Vitro: Floxuridine?(0-25 μM; 4-24 hours) is affectd by inhibitors of PARP and its sensitivity of ovarian cancer cells is enhanced. Co-exposed to FdUrd and the PARP inhibitor markedly increases killing cell numbers when its compare to treatment alone in ovarian cancer cells^[1].
Floxuridine?(300 μM; 4-24 hours) increases p-Chk1 and p-Chk2 in ovarian cancer cell lines. It may induce DNA damage and activate the ATM and ATR checkpoint signaling pathways^[1].
Floxuridine?(0-2.5 μM; 24 hours) causes a G1/S-phase arrest and following removal of the FdUrd, the G1/S-phase-arrested cells moved synchronously through S phase and into G2/M^[1].
Floxuridine is against Mueller Hinton Broth and Tryptic Soy Broth with MIC values of 0.25?μM and 0.81?μM, respectively. It also reported to be a very potent inhibitor of staphylococcal growth (MIC, 0.025-0.00313?μM)^[2].
In Vivo: Floxuridine? (intraperitoneal injection; 0.5-1.25 mg/kg; once per day for 7 days or single dose) is sufficient to show statistically significant protection against?S. aureus?infection at 0.5 mg/kg for 7 days. In addition, 1.25?mg/kg single administration of the compound shows statistically significant protection against?S. aureus?infection^[2].